NICE Recommends Lebrikizumab for Moderate to Severe Atopic Dermatitis Treatment in NHS England
UXBRIDGE, England--(BUSINESS WIRE)--Almirall S.A. (BME: ALM), a global leader in medical dermatology, announced today that the National Institute for Health ...